Biotech stocks with the lowest EV/EBIT
What the whole business costs (market value plus debt, less cash) against operating profit over the last twelve months, one-off items taken out. As of .
- Ranked
- 17
- of 146 biotech stocks we cover
- Median
- 18.8×
- Lowest
- 4.7×
- MGTX
- Range
- 4.7× to 156×
median 18.8×
4.7×156×
| # | Company | EV/EBIT | PE | Operating margin | Market cap |
|---|---|---|---|---|---|
| 1 | MGTXMeiraGTx | 4.7× | 13.1× | 46.3% | $895.1M |
| 2 | PLXProtalix BioTherapeutics | 7.5× | 11.1× | 28.9% | $206.3M |
| 3 | AGENAgenus | 8.2× | n/m | 27.3% | $294M |
| 4 | ADMAAdma Biologics | 11.3× | 15.8× | 43.8% | $2.5B |
| 5 | UTHRUnited Therapeutics | 16.3× | 21.6× | 44.4% | $25.9B |
| 6 | EXELExelixis | 16.8× | 22.1× | 39.9% | $17.4B |
| 7 | HALOHalozyme Therapeutics | 17.8× | 38.5× | 35.9% | $14.6B |
| 8 | NBIXNeurocrine Biosciences | 18.6× | 21.3× | 23.6% | $14.8B |
| 9 | REGNRegeneron Pharmaceuticals | 18.8× | 24.0× | 24.7% | $100B |
| 10 | ALNYAlnylam Pharmaceuticals | 19.2× | 26.7× | 20.8% | $21.2B |
| 11 | VRTXVertex Pharmaceuticals | 28.1× | 31.5× | 38.0% | $137.1B |
| 12 | INCYIncyte | 28.3× | 15.3× | 30.6% | $24.3B |
| 13 | KRYSKrystal Biotech | 40.1× | 37.1× | 44.9% | $8.8B |
| 14 | ONCBeOne Medicines | 40.2× | 63.2× | 15.1% | $40.2B |
| 15 | TECHBIO-TECHNE | 45.0× | 63.2× | 20.7% | $11.4B |
| 16 | VCELVericel | 110× | 88.1× | 6.0% | $2.1B |
| 17 | RGENRepligen | 156× | 237× | 8.2% | $9.8B |
Not ranked: 115 with a loss over the last year, 3 with not a meaningful number. 11 companies whose data behind this number has a caveat are left out until it is checked.
A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.